Table 1 Clinical details on patients’ cohort.
Characteristics | NOMET n (%) | SOFTMET n (%) | BONEMET n (%) | Total |
|---|---|---|---|---|
Sample size (n) | 16 | 16 | 16 | 48 |
Age (range in years) | 53–76 | 51–75 | 54–73 | 51–76 |
Menopausal status | More than 5 years since menopause (100) | 48 | ||
Lymph node involvement | Positive (100) | 48 | ||
ER status | Oestrogen receptor positive (100) | 48 | ||
Tumour grade | ||||
I | 4 (25) | 0 (0) | 0 (0) | 4 |
II | 7 (43.7) | 7 (43.7) | 4 (25) | 18 |
III | 5 (31.3) | 9 (56.3) | 12 (75) | 26 |
Tumour stage | ||||
T1 | 3 (18.7) | 7 (43.7) | 5 (31.2) | 15 |
T2 | 12 (75) | 8 (50) | 3 (18.7) | 23 |
T3 | 1 (6.3) | 1 (6.3) | 6 (37.5) | 8 |
T4 | 0 (0) | 0 (0) | 2 (12.6) | 2 |
Zoledronic acid treatment | 7 (43.7) | 10 (62.5) | 9 (56.3) | 26 |
